



DRUG	Natpara (parathyroid hormone)
Policy#	22141
Indications	Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.
CRITERIA	ConnectiCare considers Natpara to be medically necessary for patients who meet all of the following criteria:
	Hypocalcemia in adult patients with hypoparathyroidism:
	Must be prescribed by an endocrinologist AND
	 Member must have a diagnosis of hypocalcemia secondary to hypoparathyroidism Documented parathyroid levels below the lower limit of normal range, recorded on 2 separate occasions within the past 12 months AND
	 Hypocalcemia is not corrected by calcium supplements and active forms of vitamin D alone AND
	 Member is currently experiencing symptoms of disease while concurrently taking a calcium supplement and an active form of vitamin D, which are causing intolerable side effects, and member is unable to achieve target serum calcium levels (8-9mg/dL) Lab results with reference ranges must be submitted
LIMITATIONS	Natpara (parathyroid hormone) for injection therapy is not considered medically necessary for members with the following concomitant conditions:
	 Patients with hypoparathyroidism caused by calcium-sensing receptor mutations Patients with acute post-surgical hypoparathyroidism.
	The quantity limit for all strengths of Natpara (parathyroid hormone) for injection is 2 cartridges per 28 days.
REFERENCES	Natpara injection [package insert]. NPS Pharmaceuticals, Bedminster, NJ.
P&T REVIEW HISTORY	8/15, 11/15, 5/16, 5/17, 5/18, 5/19



PHARMACY PRE-AUTHORIZATION CRITERIA

DRUG	Natpara (parathyroid hormone)
REVISION RECORD	2/16